![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Switching to F/TAF (Tenofovir Alafenamide) from F/TDF (Tenofovir DF)
based Regimen Study 311-1089: 48-Week Data
|
|
|
Reported by Jules Levin
CROI 2016 Feb 21-24, Boston MA
Joel Gallant1, Eric Daar2, Francois Raffi3, Cynthia Brinson4,
Peter Ruane5, Edwin DeJesus6, Mingjin Yan 7, Andrew Plummer7, Andrew Cheng7, Martin S Rhee7
1Southwest CARE Center, Santa Fe, NM; 2Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; 3CHU Hotel Dieu-CHU De Nantes, Nantes, France; 4Central Texas Clinical Research, Austin, TX; 5Ruane Medical and Liver Health Institute, Los Angeles, CA; 6Orlando Immunology Center, Orlando, FL; 7Gilead Sciences, Foster City, CA
WEBCAST link: http://www.croiwebcasts.org/console/player/29457?mediaType=audio&
![CROI1](../images/022316/022316-15/CROI1.gif)
![CROI2](../images/022316/022316-15/CROI2.gif)
![CROI3](../images/022316/022316-15/CROI3.gif)
![CROI4](../images/022316/022316-15/CROI4.gif)
![CROI5](../images/022316/022316-15/CROI5.gif)
![CROI6](../images/022316/022316-15/CROI6.gif)
![CROI7](../images/022316/022316-15/CROI7.gif)
![CROI8](../images/022316/022316-15/CROI8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|